JP2016529319A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016529319A5 JP2016529319A5 JP2016540422A JP2016540422A JP2016529319A5 JP 2016529319 A5 JP2016529319 A5 JP 2016529319A5 JP 2016540422 A JP2016540422 A JP 2016540422A JP 2016540422 A JP2016540422 A JP 2016540422A JP 2016529319 A5 JP2016529319 A5 JP 2016529319A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrocarbyl
- pharmaceutical composition
- optionally substituted
- halo
- cyano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 36
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 36
- 239000008194 pharmaceutical composition Substances 0.000 claims 30
- 125000005843 halogen group Chemical group 0.000 claims 28
- 125000004093 cyano group Chemical group *C#N 0.000 claims 25
- 238000006467 substitution reaction Methods 0.000 claims 20
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 7
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 6
- 208000004296 neuralgia Diseases 0.000 claims 5
- 208000021722 neuropathic pain Diseases 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 208000002193 Pain Diseases 0.000 claims 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 125000004122 cyclic group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
- 208000001640 Fibromyalgia Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 229930192474 thiophene Natural products 0.000 claims 2
- 229940119498 AAK1 inhibitor Drugs 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 0 CC(CCCCCC1)CC1C(*1*2)=C*C1=CC=C2C1CCCC(C)(C)CCCC1 Chemical compound CC(CCCCCC1)CC1C(*1*2)=C*C1=CC=C2C1CCCC(C)(C)CCCC1 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361874398P | 2013-09-06 | 2013-09-06 | |
| US61/874,398 | 2013-09-06 | ||
| PCT/US2014/054298 WO2015035167A1 (en) | 2013-09-06 | 2014-09-05 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016529319A JP2016529319A (ja) | 2016-09-23 |
| JP2016529319A5 true JP2016529319A5 (enExample) | 2017-10-05 |
Family
ID=52628957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016540422A Pending JP2016529319A (ja) | 2013-09-06 | 2014-09-05 | イミダゾ［１，２−ｂ］ピリダジン系化合物、それを含む組成物、及びそれらを使用する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20150183791A1 (enExample) |
| EP (1) | EP3041473A1 (enExample) |
| JP (1) | JP2016529319A (enExample) |
| CN (1) | CN105517552A (enExample) |
| AR (1) | AR097543A1 (enExample) |
| AU (1) | AU2014315075A1 (enExample) |
| CA (1) | CA2923420A1 (enExample) |
| HK (1) | HK1217659A1 (enExample) |
| TW (1) | TW201542552A (enExample) |
| WO (1) | WO2015035167A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6473146B2 (ja) | 2013-10-11 | 2019-02-20 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ピロロトリアジンキナーゼ阻害剤 |
| HRP20240644T1 (hr) | 2014-11-06 | 2024-08-02 | Bial-R&D Investments, S.A. | Supstituirani pirazolo(1,5-a)pirimidini i njihova uporaba u liječenju medicinskih poremećaja |
| US20170333435A1 (en) | 2014-11-06 | 2017-11-23 | Lysosomal Therapeutics Inc. | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders |
| CA2966581A1 (en) | 2014-11-06 | 2016-05-12 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
| SG11201808830YA (en) | 2016-04-06 | 2018-11-29 | Lysosomal Therapeutics Inc | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| US11124516B2 (en) | 2016-04-06 | 2021-09-21 | BIAL-BioTech Investments, Inc. | Pyrrolo[1,2-A]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| JP7046827B2 (ja) | 2016-04-06 | 2022-04-04 | リソソーマル・セラピューティクス・インコーポレイテッド | イミダゾ［１，５－ａ］ピリミジニルカルボキサミド化合物および医学的障害の処置におけるその使用 |
| JP7164774B2 (ja) | 2016-05-05 | 2022-11-02 | ビアル－アール・アンド・ディ・インベストメンツ・ソシエダーデ・アノニマ | 置換イミダゾ［１，２－ｂ］ピリダジン、置換イミダゾ［１，５－ｂ］ピリダジン、関連化合物、および医学的障害の治療におけるその使用 |
| WO2017192931A1 (en) | 2016-05-05 | 2017-11-09 | Lysosomal Therapeutics Inc. | SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
| WO2018013430A2 (en) | 2016-07-12 | 2018-01-18 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus infection |
| SG11202001262QA (en) * | 2017-08-15 | 2020-03-30 | Agios Pharmaceuticals Inc | Pyruvate kinase activators for use in treating blood disorders |
| CN113164476A (zh) * | 2018-09-28 | 2021-07-23 | 代表亚利桑那大学的亚利桑那校董会 | Dyrk1/clk的小分子抑制剂及其用途 |
| US12419865B2 (en) | 2018-12-06 | 2025-09-23 | Arisan Therapeutics Inc. | Compounds for the treatment of arenavirus infection |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE460417T1 (de) * | 2005-03-23 | 2010-03-15 | Hoffmann La Roche | Acetylenylpyrazolopyrimidinderivate als mglur2- antagonsten |
| US20070078136A1 (en) * | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| CA2663091A1 (en) * | 2006-09-07 | 2008-03-13 | Biogen Idec Ma Inc. | Modulators of interleukin-1 receptor-associated kinase |
| WO2008058126A2 (en) * | 2006-11-06 | 2008-05-15 | Supergen, Inc. | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
| US20120058997A1 (en) * | 2006-11-06 | 2012-03-08 | Supergen, Inc. | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
| AR067326A1 (es) * | 2007-05-11 | 2009-10-07 | Novartis Ag | Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido |
| UY31676A1 (es) * | 2008-02-28 | 2009-09-30 | "derivados de 3-metil-imidiazo-[1,2-b]-piridazina" | |
| EA019507B1 (ru) * | 2008-05-13 | 2014-04-30 | Айрм Ллк | Конденсированные азотсодержащие гетероциклы и содержащие их композиции в качестве ингибиторов киназы |
| TWI491610B (zh) * | 2008-10-09 | 2015-07-11 | 必治妥美雅史谷比公司 | 作為激酶抑制劑之咪唑并嗒腈 |
| JP5641664B2 (ja) * | 2009-10-30 | 2014-12-17 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ | イミダゾ［１，２−ｂ］ピリダジン誘導体およびＰＤＥ１０阻害剤としてのそれらの使用 |
| KR101953210B1 (ko) * | 2011-05-19 | 2019-02-28 | 푼다시온 센트로 나시오날 드 인베스티가시오네스 온콜로기카스 카를로스Ⅲ | 단백질 키나아제 억제제로서의 대환식 화합물 |
| CA2851155C (en) * | 2011-10-14 | 2021-02-23 | Ambit Biosciences Corporation | Heterocyclic compounds and methods of use thereof |
| WO2013059589A1 (en) * | 2011-10-20 | 2013-04-25 | Sirtris Pharmaceuticals, Inc. | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
| HUE036040T2 (hu) * | 2012-03-09 | 2018-06-28 | Lexicon Pharmaceuticals Inc | Adaptor-asszociált kináz 1 gátlása fájdalom kezelésére |
| US8969565B2 (en) * | 2012-03-09 | 2015-03-03 | Lexicon Pharmaceuticals, Inc. | Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and methods of their use |
| GB201205669D0 (en) * | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| JP2016510764A (ja) * | 2013-03-07 | 2016-04-11 | カリフィア バイオ, インク.Califia Bio, Inc. | 混合系キナーゼ阻害剤および治療法 |
| WO2014160183A1 (en) * | 2013-03-13 | 2014-10-02 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Methods for modulating chemotherapeutic cytotoxicity |
-
2014
- 2014-09-03 AR ARP140103295A patent/AR097543A1/es unknown
- 2014-09-05 TW TW103130825A patent/TW201542552A/zh unknown
- 2014-09-05 JP JP2016540422A patent/JP2016529319A/ja active Pending
- 2014-09-05 EP EP14766638.2A patent/EP3041473A1/en not_active Withdrawn
- 2014-09-05 AU AU2014315075A patent/AU2014315075A1/en not_active Abandoned
- 2014-09-05 CA CA2923420A patent/CA2923420A1/en not_active Abandoned
- 2014-09-05 HK HK16105789.6A patent/HK1217659A1/zh unknown
- 2014-09-05 CN CN201480049295.XA patent/CN105517552A/zh active Pending
- 2014-09-05 WO PCT/US2014/054298 patent/WO2015035167A1/en not_active Ceased
- 2014-09-05 US US14/478,479 patent/US20150183791A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016529319A5 (enExample) | ||
| JP2015509535A5 (enExample) | ||
| JP2016529315A5 (enExample) | ||
| JP2015509534A5 (enExample) | ||
| JP2013537203A5 (enExample) | ||
| JP2015537020A5 (enExample) | ||
| JP2016540742A5 (enExample) | ||
| JP2017511321A5 (enExample) | ||
| JP2013542261A5 (enExample) | ||
| JP2016514159A5 (enExample) | ||
| EP4241772A3 (en) | Process for the preparation of compounds useful for treating spinal muscular atrophy | |
| JP2015500843A5 (enExample) | ||
| JP2016536363A5 (enExample) | ||
| JP2016530259A5 (enExample) | ||
| JP2014051526A5 (enExample) | ||
| JP2013010792A5 (enExample) | ||
| JP2016536364A5 (enExample) | ||
| JP2016519165A5 (enExample) | ||
| JP2018531941A5 (enExample) | ||
| JP2012513416A5 (enExample) | ||
| JP2016505614A5 (enExample) | ||
| BR112015004529A2 (pt) | alcóxi pirazóis como ativadores de guanilato ciclase solúvel | |
| JP2014500861A5 (enExample) | ||
| JP2015535847A5 (enExample) | ||
| JP2017504635A5 (enExample) |